发明名称 Modified beta-lactamases and methods and uses related thereto
摘要 The present invention relates to pharmaceuticals and modified beta-lactamases. Specifically, the invention relates to novel recombinant beta-lactamases and pharmaceutical compositions comprising the beta-lactamases. Also, the present invention relates to methods for modifying a beta-lactamase, producing the beta-lactamase and treating or preventing beta-lactam antibiotic induced adverse effects. Furthermore, the present invention relates to the beta-lactamase for use as a medicament and to the use of the beta-lactamase in the manufacture of a medicament for treating or preventing beta-lactam antibiotics induced adverse effects. Still further, the invention relates to a polynucleotide and a host cell comprising the polynucleotide.
申请公布号 US9034602(B2) 申请公布日期 2015.05.19
申请号 US201113699434 申请日期 2011.05.17
申请人 Synthetic Biologics, Inc. 发明人 Koski Pertti;Airaksinen Ulla;Valimaki Katja
分类号 C12N9/86;C12N9/78;A61K38/50;A61K45/06;A61K31/43;A61K31/545;A61K38/00 主分类号 C12N9/86
代理机构 Morgan, Lewis & Bockius LLP 代理人 Morgan, Lewis & Bockius LLP
主权项 1. A beta-lactamase, comprising an amino acid sequence having at least 90% sequence identity with SEQ ID NO: 1 and a hydrophilic amino acid residue other than aspartic acid (D) at a position corresponding to position 276 according to Ambler classification, wherein: the hydrophilic amino acid residue is arginine (R) and the beta-lactamase hydrolyzes ceftriaxone substantially more efficiently than a beta-lactamase of SEQ ID NO: 1 that has an aspartic acid (D) at a position corresponding to position 276 according to Ambler classification.
地址 Rockville MD US